Literature DB >> 3924550

Aggravation of ventricular arrhythmia. A drug-induced complication.

P J Podrid.   

Abstract

Each antiarrhythmic agent can cause side effects, but most of these are easily recognised by the patient or physician. However, one potentially serious side effect common to all of these drugs is aggravation of ventricular arrhythmia. Often this is without symptoms and goes unrecognised by the patient. It occurs in 11 to 16% of drug tests depending upon the method of drug evaluation employed. There are no ECG changes which predict its occurrence and blood concentrations of drug are usually within a therapeutic range. There are no clinical patient features which are associated with this toxic reaction and it does not correlate with the presence or extent of underlying heart disease, the nature of the presenting arrhythmia or the known electrophysiological properties of the antiarrhythmic drug. Careful evaluation of these drugs is therefore essential.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3924550     DOI: 10.2165/00003495-198500294-00009

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  31 in total

1.  QUINIDINE-INDUCED SYNCOPE.

Authors:  P DAVIES; D LEAK; S ORAM
Journal:  Br Med J       Date:  1965-08-28

2.  Quinidine therapy of chronic auricular fibrillation. The occurrence and mechanism of syncope.

Authors:  R ROKSETH; O STORSTEIN
Journal:  Arch Intern Med       Date:  1963-02

3.  Ventricular standstill during the intravenous procaine amide treatment of ventricular tachycardia.

Authors:  M A EPSTEIN
Journal:  Am Heart J       Date:  1953-06       Impact factor: 4.749

4.  A study of the effect of procaine amide hydrochloride in supraventricular arrhythmias.

Authors:  M C McCORD; J T TAGUCHI
Journal:  Circulation       Date:  1951-09       Impact factor: 29.690

5.  Antiarrhythmic drugs: a possible cause of out-of-hospital cardiac arrest.

Authors:  J N Ruskin; B McGovern; H Garan; J P DiMarco; E Kelly
Journal:  N Engl J Med       Date:  1983-11-24       Impact factor: 91.245

6.  Tocainide-induced ventricular fibrillation.

Authors:  R L Engler; M LeWinter
Journal:  Am Heart J       Date:  1981-04       Impact factor: 4.749

7.  Ventricular tachycardia-flutter associated with disopyramide therapy: a report of three cases.

Authors:  R W Dhurandhar; K Nademanee; A M Goldman
Journal:  Heart Lung       Date:  1978 Sep-Oct       Impact factor: 2.210

8.  Drug conversion of nonsustained ventricular tachycardia to sustained ventricular tachycardia during serial electrophysiologic studies: identification of drugs that exacerbate tachycardia and potential mechanisms.

Authors:  R L Rinkenberger; E N Prystowsky; W M Jackman; G V Naccarelli; J J Heger; D P Zipes
Journal:  Am Heart J       Date:  1982-02       Impact factor: 4.749

9.  Acute oral testing for determining antiarrhythmic drug efficacy. I. Quinidine.

Authors:  C E Gaughan; B Lown; J Lanigan; P Voukydis; H W Besser
Journal:  Am J Cardiol       Date:  1976-11-23       Impact factor: 2.778

10.  Long-term survival of patients with malignant ventricular arrhythmia treated with antiarrhythmic drugs.

Authors:  T B Graboys; B Lown; P J Podrid; R DeSilva
Journal:  Am J Cardiol       Date:  1982-09       Impact factor: 2.778

View more
  9 in total

Review 1.  Therapeutic potential of antiarrhythmic peptides. Cellular coupling as a new antiarrhythmic target.

Authors:  S Dhein; T Tudyka
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

Review 2.  Progress and prospects for optimum antiarrhythmic drug design.

Authors:  K R Courtney
Journal:  Cardiovasc Drugs Ther       Date:  1987-08       Impact factor: 3.727

3.  Cardiac electrophysiological actions of captopril: lack of direct antiarrhythmic effects.

Authors:  P D Hemsworth; R T Pallandi; T J Campbell
Journal:  Br J Pharmacol       Date:  1989-09       Impact factor: 8.739

Review 4.  Moricizine. A review of its pharmacological properties, and therapeutic efficacy in cardiac arrhythmias.

Authors:  A Fitton; M T Buckley
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

5.  Depression of maximum rate of depolarization of guinea-pig ventricular action potentials by metabolites of encainide.

Authors:  P D Hemsworth; T J Campbell
Journal:  Br J Pharmacol       Date:  1989-06       Impact factor: 8.739

6.  Electrocardiological profile and proarrhythmic effects of quinidine, verapamil and their combination: a mapping study.

Authors:  S Dhein; M Schott; E Gottwald; W Klaus
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-07       Impact factor: 3.000

Review 7.  Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias.

Authors:  R N Brogden; P A Todd
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

Review 8.  QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards.

Authors:  M Zehender; S Hohnloser; H Just
Journal:  Cardiovasc Drugs Ther       Date:  1991-04       Impact factor: 3.727

Review 9.  Encainide. A review of its pharmacological properties and therapeutic efficacy.

Authors:  R N Brogden; P A Todd
Journal:  Drugs       Date:  1987-11       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.